Top

Published in:

23-07-2023 | Melanoma | ASO Author Reflections

ASO Author Reflections: It’s About Time?

Authors: Kristen E. Rhodin, MD, MHS, Georgia M. Beasley, MD, MHS

Published in: Annals of Surgical Oncology | Issue 11/2023

Excerpt

Management of advanced melanoma has been revolutionized by effective systemic therapies.¹ Such therapies, notably immune checkpoint inhibitors (ICI), are now FDA-approved in the adjuvant setting for stage III melanoma, and even some patients with high-risk stage IIB/C disease.^2,3 However, the optimal time to initiate adjuvant ICI following oncologic resection for patients with stage III melanoma remains undefined. …

Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38(33):3947–70. https://doi.org/10.1200/JCO.20.00198.CrossRefPubMed

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma cutaneous. Updated April 11, 2022. Accessed 31 August 2022. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.

Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet. 2022;399(10336):1718–29. https://doi.org/10.1016/S0140-6736(22)00562-1.CrossRef

Rhodin KE, Jung S, Elleson K, et al. Timing of adjuvant immunotherapy in stage III melanoma, does it matter? Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13935-0.CrossRefPubMed

Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813–23. https://doi.org/10.1056/NEJMoa2211437.CrossRefPubMedPubMedCentral

Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RN. Neoadjuvant immunotherapy in melanoma: the paradigm shift. Am Soc Clin Oncol Educ Book. 2023;43:e390614. https://doi.org/10.1200/edbk_390614.CrossRefPubMed

Title: ASO Author Reflections: It’s About Time?
Authors: Kristen E. Rhodin, MD, MHS
Georgia M. Beasley, MD, MHS
Publication date: 23-07-2023
Publisher: Springer International Publishing
Keywords: Melanoma
Melanoma
Systemic Therapy
Checkpoint Inhibitors
Published in: Annals of Surgical Oncology / Issue 11/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-13960-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: It’s About Time?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2023

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort

The Era of Flat Closure Mastectomy (Is Still Here). Are You Ready?

Surgical Management of Incidentally Detected Pleural Disease in Lung Cancer Patients: A Complex Decision

ASO Author Reflections: Clinical Outcome After Upfront Curative-Intent Local Treatment of Metastases in Patient with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer

Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients

Rates and Patterns of Recurrence After Microwave Ablation of Colorectal Liver Metastases: A Per Lesion Analysis of 416 Tumors in the Era of 2.45 GHz Generators